98 related articles for article (PubMed ID: 23529925)
1. The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.
Ortúzar N
ChemMedChem; 2013 Apr; 8(4):535-7. PubMed ID: 23529925
[No Abstract] [Full Text] [Related]
2. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
Mannucci E
G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
[No Abstract] [Full Text] [Related]
3. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
Jahn E; Sausele T
Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
Elkhenini H; New JP; Summers LK; Syed AA
Eur J Intern Med; 2014 Mar; 25(3):e38-9. PubMed ID: 24412647
[No Abstract] [Full Text] [Related]
5. Current challenges in type 2 diabetes.
Garber AJ
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():1-3. PubMed ID: 22405263
[No Abstract] [Full Text] [Related]
6. Liraglutide therapy in Prader-Willi syndrome.
Cyganek K; Koblik T; Kozek E; Wojcik M; Starzyk J; Malecki MT
Diabet Med; 2011 Jun; 28(6):755-6. PubMed ID: 21388446
[No Abstract] [Full Text] [Related]
7. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
Fang V; Wazny LD; Raymond CB
CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
[No Abstract] [Full Text] [Related]
8. Insulin treatment for type 2 diabetes: when to start, which to use.
Hamaty M
Cleve Clin J Med; 2011 May; 78(5):332-42. PubMed ID: 21536829
[TBL] [Abstract][Full Text] [Related]
9. Which oral agent to use when metformin is no longer effective?
Bannon M
QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
[No Abstract] [Full Text] [Related]
10. Liraglutide (Victoza) for type 2 diabetes.
Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 analogues for type 2 diabetes.
Wilding JP; Hardy K
BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
[No Abstract] [Full Text] [Related]
12. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
Sesti G
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
Thondam SK; Cross A; Cuthbertson DJ; Wilding JP; Daousi C
Diabet Med; 2012 Aug; 29(8):e205-10. PubMed ID: 22486277
[TBL] [Abstract][Full Text] [Related]
14. [Perspective of new and future treatment of type 2 diabetes].
Sasaoka T
Nihon Rinsho; 2012 May; 70 Suppl 3():707-15. PubMed ID: 22768603
[No Abstract] [Full Text] [Related]
15. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Fabreegas B
Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
[No Abstract] [Full Text] [Related]
16. Early pharmacological intervention in newly diagnosed metabolic syndrome and type 2 diabetes.
Naruszewicz M
Przegl Lek; 2006; 63 Suppl 4():7-8. PubMed ID: 16967707
[No Abstract] [Full Text] [Related]
17. Clinical Inquiry: Which patients with metabolic syndrome benefit from metformin?
Stover L; Chi J; Kelsberg G; Safranek S
J Fam Pract; 2016 Nov; 65(11):832-834. PubMed ID: 28087869
[TBL] [Abstract][Full Text] [Related]
18. Beyond glycemic control: treating the entire type 2 diabetes disorder.
Brunton S
Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
[TBL] [Abstract][Full Text] [Related]
19. Current indications for metformin therapy.
Tankova T
Rom J Intern Med; 2003; 41(3):215-25. PubMed ID: 15526505
[TBL] [Abstract][Full Text] [Related]
20. Clinical decisions. Management of type 2 diabetes.
Goldberg RB; Holman R; Drucker DJ
N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
[No Abstract] [Full Text] [Related]
[Next] [New Search]
